Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, Phase 3 trial

AIM: Efficacy and safety of dapagliflozin plus saxagliptin (DAPA + SAXA) were compared with insulin glargine (INS) in patients with type 2 diabetes (T2D) in a 52‐week extension study. MATERIALS AND METHODS: This international Phase 3 study randomized adults with T2D on metformin with/without sulphon...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilsbøll, Tina, Ekholm, Ella, Johnsson, Eva, Garcia‐Sanchez, Ricardo, Dronamraju, Nalina, Jabbour, Serge A., Lind, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317718/
https://www.ncbi.nlm.nih.gov/pubmed/32003150
http://dx.doi.org/10.1111/dom.13981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317718/
https://www.ncbi.nlm.nih.gov/pubmed/32003150
http://dx.doi.org/10.1111/dom.13981

Ejemplares similares